Table 6.
BACE inhibitors in clinical trials for AD
| BACE inhibitors currently in phase II or III of development | |||||
|---|---|---|---|---|---|
| Agent (sponsor) | Clinicaltrials.gov identifier (trial name) | Phase | Population | Start date | Estimated end date |
| CNP520 (Novartis) | NCT02565511 (GENERATION) | II/III | Asymptomatic (homozygote APOE ε4/ε4) | 11/2015 | 08/2023 |
| E2609 (Eisai) | NCT02322021 | II | MCI to moderate AD | 11/2014 | 01/2018 |
| NCT02956486 (MISSION-AD1) | III | MCI to mild AD | 10/2016 | 06/2020 | |
| JNJ54861911 (Janssen) | NCT02406027 | II | MCI to mild AD | 07/2015 | 10/2022 |
| NCT02569398 | II/III | Preclinical (amyloid positive) | 11/2015 | 05/2023 | |
| LY3202626 (Lilly) | NCT02791191 (NAVIGATE-AD) | II | Mild AD | 06/2016 | 08/2018 |
| LY3314814 (Lilly) | NCT02245737 (AMARANTH) | II/III | MCI to mild AD | 9/2014 | 8/2019 |
| NCT02783573 (DAYBREAK ALZ) | III | Mild AD | 7/2016 | 08/2021 | |
| Verubecestat (Merck) | NCT01739348 (EPOCH) | II/III | Mild to moderate AD | 11/2012 | 06/2017 |
Abbreviations: AD, Alzheimer's disease; BACE, β-site amyloid precursor protein cleaving enzyme; MCI, mild cognitive impairment.